Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.

AbbVie invests $380 million to build two new API manufacturing facilities in North Chicago while Bora Pharmaceuticals Co., Ltd. and GSK have renewed a five-year global manufacturing partnership.

AbbVie invests $380m in North Chicago for API manufacturing, creating 300 jobs, boosting US R&D, and expanding domestic ...

Feb 23 (Reuters) - AbbVie on Monday said it would invest $380 million to build two new active pharmaceutical ingredient ...

Drilling permits issued by the Texas Railroad Commission, the state's oil and gas industry regulator.

AbbVie is investing $380 million to build two new active pharmaceutical ingredient manufacturing facilities at its headquarters campus in North Chicago. Construction is set to begin in spring 2026, ...

The growing chasm on the PGA Tour is no longer a theory but a stark reality on display this week. The Genesis Invitational ...

This is the next in the series of investments from AbbVie to expand U.S. pharmaceutical manufacturing.

Just like algae blooms in the ocean and pollen in the spring, there’s been an explosion in the past year or two of new software, related tools and lingo from the IT and mainstream/consumer side. Some ...

The Milestone Episode Features Author, Speaker, and Leadership Expert Katie Goar Reaching 100,000 followers and 100 ...

AbbVie will build two new active pharmaceutical ingredient manufacturing facilities at its North Chicago headquarters over the next three years, investing $380 million and creating 300 new full-time ...